Get In Touch
Osteoporosis, a progressive bone disease characterized by diminishing bone density and mass, primarily affects people of old age. China has the largest geriatric population in the world, and therefore, the incidence of osteoporosis is relatively high in the booming Asian country. 
According to the Ministry of Civil Affairs of China, the population in China aged 60 years and above was 193.9 million at the end of 2012, accounting for 14.3% of the total population in the country. 9.4% of the total population in China was 65 years and above, which translates to 127.14 million individuals. It is no wonder then that the osteoporosis market in China has grown tremendously from 2007 to 2015.
This research report is a comprehensive study on the status of osteoporosis in China and the overall scenario in terms of incidence, available and pipeline drugs, clinical trials, competition among vendors, demand and supply of osteoporosis drugs and therapies in the country, and opportunities available in untapped markets. 
An in-depth assessment of the industrial as well as competitive landscape is provided in the report, which takes into account key forces driving and restraining the market, and significant facts about the major market players.
Overview of the China Osteoporosis Market
According to the report, the osteoporosis market in China has registered a CAGR of 14.4% between 2007 and 2015, indicating a strong growth over the forecast period. The key factors responsible for this growth are increased number of women suffering from osteoporosis, rise in geriatric population in the country, increased awareness regarding bone disorders and overall health, higher standard of living, and rise in healthcare expenditure. In contrast, stringent norms by regulatory bodies, patent expiry of blockbuster drugs, and change in pricing owing to the presence of generic drugs are expected to impede the growth of the osteoporosis market in China
The report indicates that the development of new drugs with easy dosage patterns and the lucrative opportunities in cities such as Beijing, Shanghai, Hangzhou, and Guangzhou are projected to support the China osteoporosis market by the end of 2015.
Among the major drug classes, bisphosphonate dominated the China market. Prolia is projected to gain significance towards the end of the forecast period while parathyroid and SERM classes are expected to decline.
Companies mentioned in the research report
Some of the major domestic and international players operating in the China osteoporosis market are Merck Pharmaceutical (HK) Limited, Jiangsu Hengrui Medicine Co., Ltd., Qingdao Chiatai Haier Pharmaceutical Co., Ltd., Novartis International AG, Eli Lilly and Company, and Tongjitang Chinese Medicines Company.
By focusing on cost-effective drugs with an easy dosage pattern, players in the China osteoporosis market will be able to gain a competitive edge. The dosage schedule of traditional osteoporosis drugs is rather strict, making it difficult for patients to comply with. R&D activities aimed towards developing easy-dosage osteoporosis drugs will allow manufacturers to address the unmet medical needs of patients across China.
Segmentation based on drug class
  • Parathyroid Hormone (PTH) Therapy
    • Forteo
  • Bisphosphonates
    • Reclast/Aclasta
    • Fosamax (Alendronate)
    • Actonel (Risedronate)
    • Bonviva/Boniva (Ibandronic Acid)
  • Calcitonin
    • Miacalcin
  • Selective Estrogen Receptor Modulators (SERMs)
    • Viviant/Conbriza (Bazedoxifene)
    • Evista (Raloxifene)
  • Prolia (Denosumab)
This report gives you access to decisive data such as:
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for the coming years 
Key highlights of this report
  • Overview of key market forces propelling and restraining market growth 
  • Up-to-date analyses of market trends and technological improvements 
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors 
  • An array of graphics and SWOT analysis of major industry segments 
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis 
  • Offers a clear understanding of the competitive landscape and key product segments

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Table of Content

1. Executive Summary

2. China Osteoporosis Market
   2.1. Market Overview
   2.2. Growth Drivers and Opportunities
   2.3. Recent Market Developments
   2.4. Competitive Strategies
   2.5. Future Outlook
   2.6. Driving Factor Analysis of China Osteoporosis Market
        2.6.1. Demand Side Drivers
        2.6.2. Supply Side Drivers
        2.6.3. Restraints
        2.6.4. Opportunities
        2.6.5. Key Competitive Points

3. China Osteoporosis Market Share (2007 - 2015)
   3.1. By Drug Class - Osteoporosis Market Share & Forecast
   3.2. By Drug Market Share - Osteoporosis Market Share & Forecast

4. Osteoporosis Drugs Classes Market & Forecast (2007 - 2015)
   4.1. China Bisphosphonate Market & Forecast
   4.2. China Selective Estrogen Receptor Modulators (SERM) Market & Forecast
   4.3. China Parathyroid Hormone (PTH) Market & Forecast
   4.4. China Calcitonin Market & Forecast

5. Osteoporosis Drugs Market Analysis & Forecast (2007 - 2015)
   5.1. Bisphosphonate Drugs Market Analysis
        5.1.1. Fosamax (Alendronate)
        5.1.2. Bonviva/Boniva (Ibandronic Acid)
        5.1.3. Reclast/Aclasta
        5.1.4. Actonel (Risedronate)
   5.2. SERMs Drugs Market Analysis
        5.2.1. Evista (Raloxifene)
        5.2.2. Viviant/ Conbriza (Bazedoxifene)
   5.3. Parathyroid Hormone Drugs Market Analysis
        5.3.1. Forteo
   5.4. Calcitonin Drugs Market Analysis
        5.4.1. Miacalcin
   5.5. Prolia (Denosumab)

6. Pipeline Drugs in Osteoporosis Market Analysis
   6.1. Odanacatib (MK 0822)
   6.2. Aprela (Bazedoxifene)

7. Recommendations
   7.1. Market Strategy for Success
   7.2. Barriers to be Considered
   7.3. Future Assumption

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

China Osteoporosis Market